PDCD1 and Miyoshi myopathy: However, recent trials with the anti-PD-1 pembrolizumab in combination with an IMiD agent and dexamethasone in MM were stopped due to decreased survival and increased adverse events29,30; subsequently, all studies with CPIs and IMiD agents were temporarily stopped based on these findings.